Milgamma (Benfotiamine, Pyridoxine Hydrochloride)

Benfotiamine is a lipid‑soluble prodrug of thiamine (vitamin B1). After oral absorption it is converted to thiamine diphosphate inside cells, where it enhances carbohydrate metabolism and reduces the formation of harmful advanced glycation end‑products, helping protect nerve tissue from metabolic stress.

The appropriate dose of Milgamma is determined by the prescribing healthcare professional based on the individual’s condition, age, renal function and other factors. Dosage regimens can vary, and patients should follow the specific instructions provided by their prescriber.

Safety data for Milgamma in pregnancy and lactation are limited. Because the risk cannot be fully assessed, it should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Milgamma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Milgamma combines a thiamine prodrug (benfotiamine) with vitamin B6, targeting both carbohydrate metabolism and neurotransmitter synthesis. Compared with agents such as alpha‑lipoic acid or acetyl‑L‑carnitine, Milgamma offers a dual‑vitamin approach that may be advantageous for patients with documented B1/B6 deficiencies, while other supplements focus primarily on antioxidant or mitochondrial pathways.

Milgamma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Milgamma is taken orally, usually with a glass of water. It can be taken with or without food unless the prescriber advises otherwise. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include severe hypersensitivity reactions such as swelling, hives, or difficulty breathing, and rare worsening of neuropathic symptoms. Patients should seek immediate medical attention if they experience any signs of an allergic reaction or a sudden increase in nerve pain.

Milgamma should not be used by individuals with a known hypersensitivity to benfotiamine, pyridoxine, or any excipients in the formulation. Caution is also advised for patients with severe renal impairment, and it should be avoided during pregnancy or lactation unless clearly indicated by a physician.